Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and bosutinib

lestaurtinib has been researched along with bosutinib in 4 studies

Compound Research Comparison

Studies
(lestaurtinib)		Trials
(lestaurtinib)		Recent Studies (post-2010)
(lestaurtinib)		Studies
(bosutinib)		Trials
(bosutinib)		Recent Studies (post-2010) (bosutinib)
124126336450290

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)bosutinib (IC50)
Serine/threonine-protein kinase 10Homo sapiens (human)0.052
Tyrosine-protein kinase ABL1Homo sapiens (human)0.0422
Epidermal growth factor receptorHomo sapiens (human)0.272
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)2.6
High affinity nerve growth factor receptorHomo sapiens (human)0.022
Tyrosine-protein kinase LckHomo sapiens (human)0.0013
Tyrosine-protein kinase FynHomo sapiens (human)0.2739
NucleophosminHomo sapiens (human)0.175
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)0.358
Tyrosine-protein kinase YesHomo sapiens (human)0.0004
Tyrosine-protein kinase LynHomo sapiens (human)0.008
Tyrosine-protein kinase HCKHomo sapiens (human)0.0032
Tyrosine-protein kinase FgrHomo sapiens (human)0.0011
Mast/stem cell growth factor receptor KitHomo sapiens (human)1.886
Glycogen phosphorylase, muscle formHomo sapiens (human)0.0012
Breakpoint cluster region proteinHomo sapiens (human)0.0107
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0228
Tyrosine-protein kinase BlkMus musculus (house mouse)0.0073
Tyrosine-protein kinase FerHomo sapiens (human)0.49
Platelet-derived growth factor receptor alphaRattus norvegicus (Norway rat)4
Sodium- and chloride-dependent GABA transporter 1Rattus norvegicus (Norway rat)0.0013
Ephrin type-A receptor 2Homo sapiens (human)0.002
Ephrin type-B receptor 2Homo sapiens (human)0.0085
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.4085
Tyrosine-protein kinase CSKHomo sapiens (human)0.063
Tyrosine-protein kinase TecHomo sapiens (human)0.282
Tyrosine-protein kinase TXKHomo sapiens (human)0.04
Tyrosine-protein kinase ABL2Homo sapiens (human)0.0009
Tyrosine-protein kinase FRKHomo sapiens (human)0.0022
Tyrosine-protein kinase SYKHomo sapiens (human)0.052
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)0.0044
Ephrin type-B receptor 4Homo sapiens (human)0.0055
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.1
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)0.001
Angiopoietin-1 receptorHomo sapiens (human)1.191
Platelet-derived growth factor receptor betaRattus norvegicus (Norway rat)4
Focal adhesion kinase 1Homo sapiens (human)0.538
Tyrosine-protein kinase BTKHomo sapiens (human)0.0025
Activated CDC42 kinase 1Homo sapiens (human)0.0027
Mitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)0.0099
Serine/threonine-protein kinase 4Homo sapiens (human)0.191
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)0.184
Protein-tyrosine kinase 2-betaHomo sapiens (human)0.134
BDNF/NT-3 growth factors receptorHomo sapiens (human)0.027
Calcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)0.092
Misshapen-like kinase 1Homo sapiens (human)0.022
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)0.4185
Interleukin-1 receptor-associated kinase 4Homo sapiens (human)0.574
Serine/threonine-protein kinase TBK1Homo sapiens (human)0.5705
ALK tyrosine kinase receptorHomo sapiens (human)0.175
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2
Mitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)0.0003
Serine/threonine-protein kinase 24Homo sapiens (human)0.0039

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1
Fancher, KM; Green, MR; Newton, MD1

Reviews

1 review(s) available for lestaurtinib and bosutinib

ArticleYear
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant

2016

Other Studies

3 other study(ies) available for lestaurtinib and bosutinib

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022